Trial Profile
A Phase 1 Randomized, Prospective, Within-Subject, Double-Blind, Vehicle-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Clinical Effect of Nexagon™ in Full-Thickness Punch Wounds
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jul 2018
Price :
$35
*
At a glance
- Drugs Lufepirsen (Primary)
- Indications Wounds
- Focus Adverse reactions
- Sponsors CoDa Therapeutics Inc; OcuNexus Therapeutics
- 25 Jul 2018 According to Ocunexus Therapeutics website, CoDa Therapeutics is now called OcuNexus Therapeutics.
- 08 Dec 2014 New trial record